GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Resverlogix Corp (TSX:RVX) » Definitions » Sale Of Business

Resverlogix (TSX:RVX) Sale Of Business : C$0.00 Mil (TTM As of Mar. 2024)


View and export this data going back to 2005. Start your Free Trial

What is Resverlogix Sale Of Business?

Resverlogix's sale of business for the three months ended in Mar. 2024 was C$0.00 Mil. It means Resverlogix gained C$0.00 Mil from selling business. Resverlogix's sale of business for the trailing twelve months (TTM) ended in Mar. 2024 was C$0.00 Mil.

Compared with last quarter (C$0.00 Mil in Dec. 2023 ), Resverlogix gained the same money from selling business in Mar. 2024 (C$0.00 Mil).

Resverlogix Sale Of Business Historical Data

The historical data trend for Resverlogix's Sale Of Business can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Resverlogix Sale Of Business Chart

Resverlogix Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Dec21 Dec22 Dec23
Sale Of Business
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Resverlogix Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Sale Of Business Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Resverlogix Sale Of Business Calculation

The amount earned to sell business.


Sale Of Business for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Resverlogix Sale Of Business Related Terms

Thank you for viewing the detailed overview of Resverlogix's Sale Of Business provided by GuruFocus.com. Please click on the following links to see related term pages.

Resverlogix (TSX:RVX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Resverlogix Corp (TSX:RVX) » Definitions » Sale Of Business
Comparable Companies
TSXV:SBM XCNQ:BETR TSX:ATE TSX:AEZS XCNQ:ASEP XCNQ:PREV TSXV:KNE XCNQ:MDMA XCNQ:PHRM XCNQ:BIOV OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
RVXCF:USA RFS:Germany
Address
4820 Richard Road South West, Suite 300, Calgary, AB, CAN, T3E 6L1
Website
https://www.resverlogix.com
Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.
Executives
Aaron Bradley Cann Senior Officer

Resverlogix (TSX:RVX) Headlines

No Headlines